

## Patrys to Present at German Hematology Congress

- **PAT-SM6 clinical trial data to be presented at the Annual Meeting of the German, Austrian and Swiss Associations for Hematology and Medical Oncology**
- **Acceptance of oral lecture reflects the strong interest in the clinical trial data by the oncology community**

**Melbourne, Australia; 18 August, 2014:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company has announced that results related to its novel anti-cancer PAT-SM6 multiple myeloma trial in relapsed and refractory patients has been accepted for presentation as a lecture at the Annual Meeting of the German, Austrian and Swiss Associations for Hematology and Medical Oncology in Hamburg, to be held on 11 October 2014.

The results from the clinical trial investigating the use of PAT-SM6 in relapsed/refractory multiple myeloma patients will be presented by lead clinical investigator Dr. Leo Rasche of the Department of Haematology and Oncology, University Hospital of Würzburg. The oral lecture is titled "Clinical activity of PAT-SM6 monoclonal antibody in advanced and extramedullary Multiple Myeloma – Results from a Phase I study and a single patient treatment use".

The clinical trial data showed that PAT-SM6 was well tolerated with no serious adverse events. Four out of 12 patients experienced disease stabilisation (SD), which was maintained in two patients for more than 120 days. Interestingly, in the group of patients with SD an increase in CD8+ T-cells and NIK cells could be observed, indicating a possible clinically relevant cross-talk between PAT-SM6 and cellular immunity. PAT-SM6 was also utilised on an "individual treatment basis" in combination with lenalidomide and bortezomib, which led to a rapid response in a single case of asecretory extramedullary multiple myeloma, resulting in disappearance of lesions and intramedullary manifestations in PET-CT scans.

Patrys' abstract for the Annual Meeting of the German, Austrian and Swiss Associations for Hematology and Medical Oncology will appear as part of a supplement issue in the journal "Oncology Research and Treatment" (formerly "Oncology") by S. Karger on at the following website <http://www.karger.com/Journal/Home/224106> after the Congress. The abstract is currently available online at <http://www.haematologie-onkologie-2014.com/haupt/programm> and can be found by viewing the Congress programme. The lecture is taking place during the session on Saturday, October 11, commencing at 12 noon in room Saal D. The session is entitled "*Multipler Myelom – klinisch*" (Lecture Code V72, Abstract 768).

Patrys CEO, Dr. Marie Roskrow, said: "The German congress is a preeminent international forum and we are delighted to have been selected to participate in the oral presentation session at this conference, and we look forward to the opportunity to provide an update on our PAT-SM6 programme".

Lead clinical investigator, Dr. Leo Rasche, said: "Targeting GRP78 with monoclonal antibodies provides a promising approach for resistant disease in multiple myeloma. Combination of PAT-SM6 with a proteasome inhibitor will be studied in the planned upcoming trial".

**-Ends-**



**For further information, please contact:**

*Patrys Limited:*

Dr. Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

*Patrys IR:*

Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

*Patrys Media:*

Kellie Hanrick  
Buchan Consulting  
P: +61 3 9866 4722  
[ktanrick@buchanwe.com.au](mailto:ktanrick@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com)